Pyxis Oncology (PYXS) Other financing activities (2021 - 2023)

Pyxis Oncology (PYXS) reported Other financing activities of $52000.0 for Q4 2023, down 96.98% quarter-over-quarter from $1.7 million in Q3 2021.

Pyxis Oncology (PYXS) Other financing activities (2021 - 2023) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Other financing activities data on file, last reported at $52000.0 in Q4 2023.

Other financing activities for Q4 2023 came in at $52000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $2.5 million (changed N/A YoY), and the FY2023 annual result was $445000.0, changed N/A from the prior year.
Other financing activities eased to $52000.0 in Q4 2023 per PYXS's latest filing, from $1.7 million in the prior quarter.
Over five years, Other financing activities peaked at $1.7 million in Q3 2021 and troughed at $52000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Pyxis Oncology	125.84 Mn	108.95 Mn	8.65 Mn

Download Data